The similar phenotypic effects of specific DR4 receptor internalization during long period of combined treatment with TRAIL and bortezomib was observed in breast cancer cells MDA-MB-231where almost 5 fold reduction of DR4 receptor on the cell surface was observed after 24 h incubation (Fig. S2). The gene discussed is TNFSF10; the disease is breast cancer.